{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.2","value":"88.7"},{"groupId":"OG001","spread":"42.3","value":"97.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms with at least one post-baseline PK sample. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Cycle length=21 days)","title":"Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1","type":"SECONDARY","unitOfMeasure":"μg/mL"}